Soraya Mezouar

Dr. Soraya Mezouar

Microbe Evolution Phylogeny Infection, Institut pour la Recherche et le Developpement, Assistance Publique Hopitaux de Marseille, Aix-Marseille University, 13005 Marseille, France
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2012 in Blood
Verified
Journal Article
Open access
PDF file
RDRoxane Darbousset
Roxane Darbousset
GTGrace M. Thomas
Grace M. Thomas
SMSoraya Mezouar
Soraya Mezouar
CFCorinne Frère
Corinne Frère
RBRénaté Bonier
Rénaté Bonier
LPLaurence Panicot-Dubois
Laurence Panicot-Dubois
For a long time, blood coagulation and innate immunity have been viewed as interrelated responses. Recently, the presence of leukocytes at the sites of vessel injury has been described. Here we analyzed interaction of neutrophils, monocytes, and platelets in thrombus formation after a laser-induced injury in vivo. Neutrophils immediately adhered to injured vessels, preceding platelets, by binding to the activated endothelium via leukocyte function antigen-1–ICAM-1 interactions. Monocytes rolled on a thrombus 3 to 5 minutes postinjury. The kinetics of thrombus formation and fibrin generation were drastically reduced in low tissue factor (TF) mice whereas the absence of factor XII had no effect. In vitro, TF was detected in neutrophils. In vivo, the inhibition of neutrophil binding to the vessel wall reduced the presence of TF and diminished the generation of fibrin and platelet accumulation. Injection of wild-type neutrophils into low TF mice partially restored the activation of the blood coagulation cascade and accumulation of platelets. Our results show that the interaction of neutrophils with endothelial cells is a critical step preceding platelet accumulation for initiating arterial thrombosis in injured vessels. Targeting neutrophils interacting with endothelial cells may constitute an efficient strategy to reduce thrombosis.

1 March 2016 in Thrombosis Research
Verified
Journal Article
Closed access
SMSoraya Mezouar
Soraya Mezouar
CFCorinne Frère
Corinne Frère
RDRoxane Darbousset
Roxane Darbousset
DMDiane Mege
Diane Mege
LCLydie Crescence
Lydie Crescence
Christophe DuboisChristophe Dubois
Christophe Dubois

29 May 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SMSoraya Mezouar
Soraya Mezouar
RDRoxane Darbousset
Roxane Darbousset
FDFrançoise Dignat‐George
Françoise Dignat‐George
LPLaurence Panicot-Dubois
Laurence Panicot-Dubois
Christophe DuboisChristophe Dubois
Christophe Dubois
Venous thromboembolism constitutes one of the main causes of death during the progression of a cancer. We previously demonstrated that tissue factor (TF)-bearing cancer cell-derived microparticles accumulate at the site of injury in mice developing a pancreatic cancer. The presence of these microparticles at the site of thrombosis correlates with the size of the platelet-rich thrombus. The objective of this study was to determine the involvement of TF expressed by cancer cell-derived microparticles on thrombosis associated with cancer. We observed that pancreatic cancer cell derived microparticles expressed TF, its inhibitor tissue factor pathway inhibitor (TFPI) as well as the integrins αvβ1 and αvβ3. In mice bearing a tumor under-expressing TF, a significant decrease in circulating TF activity associated with an increase bleeding time and a 100-fold diminished fibrin generation and platelet accumulation at the site of injury were observed. This was mainly due to the interaction of circulating cancer cell-derived microparticles expressing TFPI with activated platelets and fibrinogen. In an ectopic model of cancer, treatment of mice with Clopidogrel, an anti-platelet drug, decreased the size of the tumors and restored hemostasis by preventing the accumulation of cancer cell-derived microparticles at the site of thrombosis. In a syngeneic orthotopic model of pancreatic cancer Clopidogrel also significantly inhibited the development of metastases. Together, these results indicate that an anti-platelet strategy may efficiently treat thrombosis associated with cancer and reduce the progression of pancreatic cancer in mice.

7 May 2015 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
GTG. M. Thomas
G. M. Thomas
Alexander BrillAlexander Brill
Alexander Brill
SMSoraya Mezouar
Soraya Mezouar
LCL. Crescence
L. Crescence
MGM. Gallant
M. Gallant
DWDenisa Wagner
Denisa Wagner
Background The risk of thrombotic complications such as deep vein thrombosis (DVT) during tumor development is well known. Tumors release into the circulation procoagulant microparticles (MPs) that can participate in thrombus formation following vessel injury. The importance of this MP tissue factor (TF) in the initiation of cancer‐associated DVT remains uncertain. Objective To investigate how pancreatic cancer MPs promote DVT in vivo. Methods We combined a DVT mouse model in which thrombosis is induced by flow restriction in the inferior vena cava with one of subcutaneous pancreatic cancer in C57BL/6J mice. We infused high‐TF and low‐TF tumor MPs to determine the importance of TF in experimental cancer‐associated DVT. Results Both tumor‐bearing mice and mice infused with tumor MPs subjected to 3 h of partial flow restriction developed an occlusive thrombus; fewer than one‐third of the control mice did. We observed that MPs adhered to neutrophil extracellular traps (NETs), which are functionally important players during DVT, whereas neither P‐selectin nor glycoprotein Ib were required for MP recruitment in DVT. The thrombotic phenotype induced by MP infusion was suppressed by hirudin, suggesting the importance of thrombin generation. TF carried by tumor MPs was essential to promote DVT, as mice infused with low‐TF tumor MPs had less thrombosis than mice infused with high‐TF tumor MPs. Conclusions TF expressed on tumor MPs contributes to the increased incidence of cancer‐associated venous thrombosis in mice in vivo. These MPs may adhere to NETs formed at the site of thrombosis.

1 June 2014 in Seminars in Oncology
Verified
Journal Article
Closed access
SMSoraya Mezouar
Soraya Mezouar
DMDiane Mege
Diane Mege
RDRoxane Darbousset
Roxane Darbousset
DFDominique Farge
Dominique Farge
PDPhilippe M. Debourdeau
Philippe M. Debourdeau
Christophe DuboisChristophe Dubois
Christophe Dubois

5 November 2021 in Autophagy
Verified
Journal Article
Open access
SBSonia Brun
Sonia Brun
EBEloïne Nadeige Bestion
Eloïne Nadeige Bestion
EREric Raymond
Eric Raymond
FBFiras Bassissi
Firas Bassissi
ZJZuzana Macek Jilkova
Zuzana Macek Jilkova
PHPhilippe Halfon
Philippe Halfon
Hepatocellular carcinoma is the most frequent primary liver cancer. Macroautophagy/autophagy inhibitors have been extensively studied in cancer but, to date, none has reached efficacy in clinical trials. In this study, we demonstrated that GNS561, a new autophagy inhibitor, whose anticancer activity was previously linked to lysosomal cell death, displayed high liver tropism and potent antitumor activity against a panel of human cancer cell lines and in two hepatocellular carcinoma in vivo models. We showed that due to its lysosomotropic properties, GNS561 could reach and specifically inhibited its enzyme target, PPT1 (palmitoyl-protein thioesterase 1), resulting in lysosomal unbound Zn2+ accumulation, impairment of cathepsin activity, blockage of autophagic flux, altered location of MTOR (mechanistic target of rapamycin kinase), lysosomal membrane permeabilization, caspase activation and cell death. Accordingly, GNS561, for which a global phase 1b clinical trial in liver cancers was just successfully achieved, represents a promising new drug candidate and a hopeful therapeutic strategy in cancer treatment. Abbreviations: ANXA5:annexin A5; ATCC: American type culture collection; BafA1: bafilomycin A1; BSA: bovine serum albumin; CASP3: caspase 3; CASP7: caspase 7; CASP8: caspase 8; CCND1: cyclin D1; CTSB: cathepsin B; CTSD: cathepsin D; CTSL: cathepsin L; CQ: chloroquine; iCCA: intrahepatic cholangiocarcinoma; DEN: diethylnitrosamine; DMEM: Dulbelcco’s modified Eagle medium; FBS: fetal bovine serum; FITC: fluorescein isothiocyanate; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; HDSF: hexadecylsulfonylfluoride; IC50: mean half-maximal inhibitory concentration; LAMP: lysosomal associated membrane protein; LC3-II: phosphatidylethanolamine-conjugated form of MAP1LC3; LMP: lysosomal membrane permeabilization; MALDI: matrix assisted laser desorption ionization; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MKI67: marker of proliferation Ki-67; MTOR: mechanistic target of rapamycin kinase; MRI: magnetic resonance imaging; NH4Cl: ammonium chloride; NtBuHA: N-tert-butylhydroxylamine; PARP: poly(ADP-ribose) polymerase; PBS: phosphate-buffered saline; PPT1: palmitoyl-protein thioesterase 1; SD: standard deviation; SEM: standard error mean; vs, versus; Zn2+: zinc ion; Z-Phe: Z-Phe-Tyt(tBu)-diazomethylketone; Z-VAD-FMK: carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone.